

21 ⁵Laboratory of Biological Agents, Faculty of Medicine, Meritorious Autonomous
22 University of Puebla, Puebla, Puebla, México

23 ⁶Department of General Surgery, University Hospital of Puebla, Puebla, Puebla,
24 Mexico

25

26 *Corresponding author

27 Email: diazorea@yahoo.com.mx (MADO)

28 Email: hectroyano@hotmail.com (HADH)

29

30 [¶]These authors contributed equally to this work.

31 [&]These authors also contributed equally to this work.

32

33

34

35

36

37

38

39

40

41

42

43

44 **Abstract**

45 **Introduction:** Gastric cancer remains an important health problem. It's
46 molecular mechanisms and interactions with the immune system are still not well
47 elucidated. Therefore, we aimed to evaluate the concentration and profile of
48 serum proteins and immunoglobulins in Mexican patients with advanced gastric
49 cancer. **Materials and methods:** We performed a descriptive study. Adult
50 patients from both sexes were included. The problem group was formed of
51 patients with advanced gastric cancer and the control group was formed of
52 healthy subjects. Demographic data, gastric cancer histological type and stage of
53 tumor node metastasis (TNM) system were recorded. The profile and
54 concentration of serum proteins and immunoglobulins was determined and
55 analyzed in different subgroups classified by sex, histologic type and stage of
56 TNM system. To compare the concentrations of serum proteins and
57 immunoglobulins the ANOVA test was performed. A $p < 0.05$ was considered
58 statistically significant. **Results:** We included 88 patients with advanced gastric
59 cancer and 74 healthy controls. There were no differences in demographic data
60 among the groups, and the most common gastric cancer type was the diffuse
61 (67.04%). Women with gastric cancer from any type presented higher levels of
62 immunoglobulin G (IgG) compared with the control group ($p < 0.001$) and men
63 with gastric cancer of intestinal type in TNM stage III presented higher levels of
64 IgG compared with it's counterpart of diffuse type ($p < 0.001$). Also, patients with
65 intestinal type gastric cancer presented higher concentrations of alpha-1
66 globulins compared with patients with the diffuse type ($p < 0.05$). Finally, patients

67 with diffuse gastric cancer TNM stage IV presented the lowest albumin/globulin
68 ratios. **Conclusion:** There is a greater concentration of serum IgG in some
69 subgroups of patients with advanced gastric cancer, the concentration of alpha-1
70 globulins is different between the intestinal and diffuse types and the
71 albumin/globulin ratio is lower in the diffuse type.

72

73 **Keywords:** gastroenterology; oncology; immunology; gastro-intestinal
74 malignancies; serum protein electrophoresis; enzyme-linked immuno-sorbent
75 assay.

76

77

78

79

80

81

82

83

84

85

86

87

88 Introduction

89 Gastric cancer (GC) remains an important health problem. It is one of the
90 most common causes of cancer and one of the leading causes of cancer-related
91 death worldwide [1]. The Lauren classification sub-classifies GC into diffuse,
92 intestinal and mixed type, each one with different pathological characteristics and
93 prognosis [2-5]. Despite the great advances that have been made in the
94 diagnosis and treatment of gastric cancer, its prognosis remains poor as it is a
95 disease with nonspecific clinical manifestations in early stages, and then, it is
96 usually diagnosed in advanced stages when it is no longer possible to offer
97 curative therapies [6]. Hence, it remains relevant to study the molecular
98 mechanisms regulating the development of gastric cancer and to identify new
99 molecular targets for early detection and targeted treatments.

100 Several experimental studies have been performed with this approach, the
101 vast majority directed to the detection of over-expression or anomalies in surface
102 molecules and molecules from cellular secretion. Many of the studies have not
103 shown satisfactory results, however, many others have favored the development
104 of new treatments [7]. The changes in the expression of the cell surface
105 molecules of malignant cells leads to a loss in the immunological tolerance,
106 which triggers immunological responses against them. Although these
107 anomalous changed molecules can be identified both in the interior and in the
108 surface of the malignant cells, the antigens on the surface of the tumor are the
109 mains responsible of the tumor immunogenicity [8-9].

110 Some studies have been carried out on the evaluation of the interaction
111 between gastric cancer and the immune response. The local humoral
112 immunological response has been studied, and it has been observed that in the
113 cytoplasm of the advanced gastric cancer tumor cells there is less
114 immunoglobulin M (IgM) and immunoglobulin A (IgA) distribution than in the cells
115 of early gastric cancer and intestinal metaplasia. Similarly, it has been observed
116 that in the stroma of advanced gastric cancer there is less infiltration of positive
117 plasma cells for immunoglobulin G, (IgG), IgM and IgA, than in the stroma of
118 early gastric cancer [10]. However, tissue levels of IgA in the unaffected stomach
119 of patients with gastric cancer are elevated compared to healthy controls [11].
120 Regarding the systemic humoral immunological response, it has been observed
121 that patients with gastric cancer have lower levels of globulins and IgG in
122 comparison with healthy patients [12]. Moreover, different correlations have been
123 established between gastric cancer and the humoral immune response. For
124 example, it has been observed that depending on the stage of the disease and
125 the immunoglobulin allotypes, the levels of antibodies against the membrane
126 glycoprotein mucin 1 (MUC1), which is overexpressed in gastric cancer tumor
127 cells, may be elevated [13]. Also, high levels of antibodies against the Thomsen-
128 Friedenreich glycotope related to MUC1 have been observed in some cases and
129 associated with a less aggressive course of the disease [14].

130 To date, there is no study that has evaluated the levels of globulins and
131 immunoglobulins in patients with advanced gastric cancer in relation to the
132 Lauren's classification, which would help in further understanding the humoral

133 immune response in this disease. Therefore, we aimed to evaluate the
134 concentration and profile of serum proteins and immunoglobulins in Mexican
135 patients with intestinal and diffuse advanced gastric cancer.

136

137 **Materials and methods**

138 **Study type and population**

139 We performed an observational, transversal, comparative and analytical
140 study. Patients of both sexes from 20 to 85 years were included. The problem
141 group was formed of patients from the High Specialty Medical Unit “Manuel Ávila
142 Camacho”, Puebla, Mexico, with the diagnosis of gastric cancer in stages III and
143 IV, according to the tumor node metastasis (TNM) system. The control group
144 was formed of healthy volunteers. We excluded patients with
145 immunosuppressive states as diabetes mellitus, autoimmune diseases, primary
146 or secondary immunodeficiencies and patients on chemotherapy or radiotherapy.
147 The recruitment period was from August 1st, 2016 to July 31st, 2018.

148 **Ethics approval and informed consent**

149 This study was approved by the research and ethics committee of the
150 School of Medicine of the Meritorious Autonomous University of Puebla, Puebla,
151 Mexico, whit number 526 and written informed consent was obtained from all
152 participants.

153 **Quantification of total proteins**

154 **Total proteins**

155 The concentration of total proteins was determined by spectrophotometry
156 by the Biuret technique following the instructions of Krueziger [15,16]. The biuret
157 method is based on the formation of a colored copper protein complex which is
158 measured by spectroscopy absorbance at 540 nm. A standard concentration
159 curve was made using bovine serum albumin (BSA) before each determination to
160 compare the absorbances of the samples. The absorbance of the color produced
161 was read at 540 nm. The total protein concentration was recorded in g/dL.

162 **Determination and quantification of protein fractions**

163 **Serum protein electrophoresis in cellulose acetate**

164 The protein fractions were determined by electrophoresis in cellulose
165 acetate according to the standard method of the Analysis of Serum Protein, with
166 Veronal buffer, pH 8.6, at an ionic strength of 0.05 [17]. Staining was done with
167 Ponceau red. The concentration of each fraction (albumin, alpha-1 globulin,
168 alpha-2 globulin, beta globulin and gamma globulin) was determined in a Bio-
169 Rad Gel DocTM XR⁺ Gel Documentation System and reported in g/dL.

170 **Determination and quantification of immunoglobulins**

171 **Enzyme-Linked Immuno-Sorbent Assay (ELISA)**

172 The concentrations of serum immunoglobulins were determined by the
173 Enzyme-linked Immunosorbent Assay (ELISA). The ELISA kits of eBioscience™
174 for Human IgM, IgG and IgA total (ELISA Ready-SET-Go!™ Kit) were used
175 following the provider's instructions. The concentration of the IgM, IgG and IgA
176 values were recorded in mg/dL.

177 **Statistical analysis**

178 We determined a sample size of 88 patients to achieve an alpha error of
179 0.05 and a power of 90%. We recorded general variables of age, sex, gastric
180 cancer type of Lauren's classification and stage of TNM classification.
181 Demographic data are presented as numbers with percentages for categorical
182 variables and mean with standard deviation for numerical variables. For the
183 comparison between the groups, the X^2 test and Student's-t test were used as
184 appropriate. The values of the determinations of total protein, albumin, alpha-1
185 globulin, alpha-2 globulin, beta globulin, gamma globulin, IgM, IgG and IgA were
186 recorded. For the comparison between groups of the values of proteins, its
187 fractions and immunoglobulins, the ANOVA test for three groups was performed.
188 A $p < 0.05$ was considered as statistically significant. The SPSS software
189 V.20.0.0.0 was used.

190

191 Results

192 We included 88 patients with gastric cancer and 74 healthy controls. Among
 193 the patients with gastric cancer, 24 (27.27%) were intestinal type, 59 (67.04%)
 194 were diffuse type and 5 (5.68%) were not classified. There were no differences
 195 between age and sex among the different gastric cancer types; however, there
 196 were more patients with stage IV disease in the intestinal type group (Table 1).

197

198 **Table 1. Demographic characteristics of patients with gastric cancer**
 199 **from the different types.**

	Total Gastric Cancer Patients (intestinal and diffuse types) (n=83)	Intestinal Gastric Cancer Patients (n=24)	Diffuse Gastric Cancer Patients (n=59)	Healthy Controls (n=74)	p value
Age, m (SD)	54.00 (11.84)	54.87 (11.65)	53.97 (12.00)	38.16 (14.75)	0.758 ^a
Sex					0.868 ^b
Men, n (%)	47 (56.62)	13 (54.2)	34 (57.6)	37 (50.0)	
Women, n (%)	36 (43.37)	11 (45.8)	25 (42.4)	37 (50.0)	
TNM Stage					<0.001 ^b
III	10 (12.04)	3 (12.5)	7 (11.9)		
IV	71 (85.54)	21 (87.5)	50 (84.7)		

200 Abbreviations: m, median; SD, standard deviation; n, number; %, percentage;

201 TNM, tumor node metastasis.

202 ^aStudent's-t test between intestinal and diffuse gastric cancer patients.

203 ^bChi-squared test between intestinal and diffuse gastric cancer patients.

204

205 **Patients with gastric cancer compared with healthy** 206 **controls**

207 We compared the concentration of the serum proteins and
208 immunoglobulins between the patients with gastric cancer and the healthy
209 controls. Only the women with gastric cancer presented higher levels of IgG
210 compared with the women healthy control group, the remainder presented no
211 differences. All comparisons are shown in Table 2.

212

213 **Table 2. Levels of proteins, albumin, globulins and immunoglobulins**
214 **between patients with gastric cancer and healthy controls.**

	Gastric Cancer Patients	Healthy controls	p value
Total	(n=88)	(n=74)	
Proteins (g/dL), m (SD)	6.62 (1.87)	7.84 (0.94)	>0.05 ^a
Albumin (g/dL), m (SD)	3.64 (1.20)	4.39 (0.66)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.18 (0.15)	0.14 (0.10)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.53 (0.22)	0.53 (0.16)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.54 (0.24)	0.69 (0.21)	>0.05 ^a

Gamma globulin (g/dL), m (SD)	1.68 (0.88)	1.84 (0.42)	>0.05 ^a
IgM (g/dL), m (SD)	121.35 (44.10)	142.64 (42.58)	>0.05 ^a
IgG (g/dL), m (SD)	2102.41 (526.15)	2065.77 (438.82)	>0.05 ^a
IgA (g/dL), m (SD)	356.27 (29.78)	356.68 (25.22)	>0.05 ^a
Men	(n=49)	(n=37)	
Proteins (g/dL), m (SD)	6.94 (2.10)	8.11 (1.08)	>0.05 ^a
Albumin (g/dL), m (SD)	3.82 (1.34)	4.51 (1.04)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.17 (0.14)	0.44 (0.34)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.55 (0.24)	0.88 (0.83)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.54 (0.25)	1.02 (0.21)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.80 (0.97)	1.24 (0.30)	>0.05 ^a
IgM (g/dL), m (SD)	117.79 (42.77)	132.29 (47.93)	>0.05 ^a
IgG (g/dL), m (SD)	2016.04 (546.81)	2121.35 (446.26)	>0.05 ^a
IgA (g/dL), m (SD)	361.20 (31.34)	360.99 (22.16)	>0.05 ^a
Women	(n=39)	(n=37)	
Proteins (g/dL), m (SD)	6.32 (1.49)	7.56 (0.69)	>0.05 ^a
Albumin (g/dL), m (SD)	3.42 (0.96)	4.06 (0.84)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.18 (0.15)	0.37 (0.18)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.51 (0.19)	0.84 (0.23)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.53 (0.21)	1.02 (0.23)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.54 (0.73)	1.26 (0.21)	>0.05 ^a
IgM (g/dL), m (SD)	125.74 (45.86)	153.00 (34.05)	>0.05 ^a

IgG (g/dL), m (SD)	2208.71 (485.48)	2030.00 (432.47)	<0.001 ^a
IgA (g/dL), m (SD)	350.20 (26.90)	352.37 (27.58)	>0.05 ^a

215 Abbreviations: m, median; SD, standard deviation; n, number; %, percentage;

216 IgM, immunoglobulin M; IgG, immunoglobulin G; IgA, immunoglobulin A.

217 ^aOne-way ANOVA.

218

219 **Patients with intestinal type gastric cancer compared**
 220 **with patients with diffuse type gastric cancer**

221 We compared the concentration of the serum proteins and
 222 immunoglobulins between the patients with intestinal type gastric cancer and the
 223 patients with diffuse type gastric cancer. In the patients with intestinal type the
 224 concentrations of alpha-1 globulins were higher. The remainder groups of
 225 albumin, globulins and immunoglobulins did not present differences. All
 226 comparisons are shown in Table 3.

227

228 **Table 3. Levels of proteins, albumin, globulins and immunoglobulins**

229 **between patients with gastric cancer from the different types.**

	Intestinal Gastric Cancer Patients	Diffuse Gastric Cancer Patients	p value
Total	(n=24)	(n=59)	
Proteins (g/dL), m (SD)	6.0 (1.46)	7.01 (2.04)	<0.05 ^a
Albumin (g/dL), m (SD)	3.37 (1.02)	3.79 (1.28)	>0.05 ^a

Alpha-1 globulin (g/dL), m (SD)	0.22 (0.19)	0.15 (0.12)	<0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.45 (0.10)	0.55 (0.25)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.46 (0.20)	0.56 (0.26)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.48 (0.83)	1.78 (0.93)	>0.05 ^a
IgM (g/dL), m (SD)	108.75 (33.36)	122.67 (46.12)	>0.05 ^a
IgG (g/dL), m (SD)	2165.00 (537.12)	2039.05 (527.56)	>0.05 ^a
IgA (g/dL), m (SD)	353.45 (31.49)	359.22 (29.31)	>0.05 ^a

230 Abbreviations: m, median; SD, standard deviation; IgM, immunoglobulin M; IgG,
 231 immunoglobulin G; IgA, immunoglobulin A.

232 ^aOne-way ANOVA.

233

234 **Patients with TNM stage III gastric cancer compared**
 235 **with patients with TNM stage IV gastric cancer**

236 We compared the concentration of the serum proteins and
 237 immunoglobulins between the patients with TNM stage III gastric cancer and the
 238 patients with TNM stage IV gastric cancer. There were no differences in the
 239 levels of proteins, albumin, globulins and immunoglobulins between these
 240 groups. All comparisons are shown in Table 4.

241

242 **Table 4. Levels of proteins, albumin, globulins and immunoglobulins**
 243 **between patients with gastric cancer from different stages.**

	TNM Stage III	TNM Stage IV	p value
--	----------------------	---------------------	----------------

Total	(n=10)	(n=71)	
Proteins (g/dL), m (SD)	6.68 (1.64)	6.62 (1.98)	>0.05 ^a
Albumin (g/dL), m (SD)	3.64 (0.89)	3.65 (1.28)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.17 (0.14)	0.17 (0.15)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.63 (0.19)	0.51 (0.22)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.54 (0.25)	0.53 (0.24)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.55 (0.61)	1.72 (0.93)	>0.05 ^a
IgM (g/dL), m (SD)	115.30 (30.86)	120.91 (45.57)	>0.05 ^a
IgG (g/dL), m (SD)	2017.00 (648.57)	2110.56 (515.76)	>0.05 ^a
IgA (g/dL), m (SD)	346.10 (36.58)	357.22 (28.59)	>0.05 ^a

244 Five patients with undetermined gastric cancer type were excluded and 2
 245 patients with gastric cancer TNM stage II were excluded. Abbreviations: TNM,
 246 tumor node metastasis; m, median; SD, standard deviation; IgM, immunoglobulin
 247 M; IgG, immunoglobulin G; IgA, immunoglobulin A.

248 ^aOne-way ANOVA.

249

250 **Patients with intestinal type gastric cancer compared**
 251 **with patients with diffuse type gastric cancer, stratified**
 252 **by TNM stage**

253 We performed an analysis to evaluate differences in the concentration of
 254 the serum proteins and immunoglobulins between the intestinal and diffuse types
 255 of gastric cancer, stratified by the TNM stage. Only, in the sub-group of men with

256 gastric cancer from the intestinal type in TNM stage III there was an increased
 257 level of IgG. The remainder presented no differences. All comparisons are shown
 258 in Tables 5 and 6.

259

260 **Table 5. Levels of proteins, albumin, globulins and immunoglobulins**
 261 **between patients with gastric cancer TNM stage III from the different types.**

	Intestinal Gastric Cancer Patients	Diffuse Gastric Cancer Patients	p value
Total	(n=3)	(n=7)	
Proteins (g/dL), m (SD)	6.26 (2.31)	6.85 (1.47)	>0.05 ^a
Albumin (g/dL), m (SD)	3.50 (1.20)	3.70 (0.83)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.26 (0.14)	0.14 (0.14)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.48 (0.07)	0.69 (0.20)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.37 (0.03)	0.62 (0.28)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.59 (0.93)	1.54 (0.51)	>0.05 ^a
IgM (g/dL), m (SD)	133.00 (49.12)	107.71 (20.02)	>0.05 ^a
IgG (g/dL), m (SD)	2286.66 (641.27)	1901.42 (664.79)	>0.05 ^a
IgA (g/dL), m (SD)	369.00 (19.05)	336.28 (38.88)	>0.05 ^a
Men	(n=2)	(n=4)	
Proteins (g/dL), m (SD)	7.35 (1.90)	6.87 (1.63)	>0.05 ^a
Albumin (g/dL), m (SD)	4.04 (1.07)	3.79 (0.95)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.34 (0.02)	0.05 (0.08)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.49 (0.09)	0.64 (0.15)	>0.05 ^a

Beta globulin (g/dL), m (SD)	0.39 (0.00)	0.47 (0.13)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	2.01 (0.82)	1.68 (0.58)	>0.05 ^a
IgM (g/dL), m (SD)	109.50 (38.89)	109.50 (25.52)	>0.05 ^a
IgG (g/dL), m (SD)	2630.00 (339.41)	1552.50 (397.61)	<0.001 ^a
IgA (g/dL), m (SD)	374.50 (23.33)	340.25 (49.50)	>0.05 ^a
Women	(n=1)	(n=3)	
Proteins (g/dL), m (SD)	4.10 (0.00)	6.83 (1.59)	ND
Albumin (g/dL), m (SD)	2.42 (0.00)	3.58 (0.83)	ND
Alpha-1 globulin (g/dL), m (SD)	0.10 (0.00)	0.25 (0.12)	ND
Alpha-2 globulin (g/dL), m (SD)	0.46 (0.00)	0.76 (0.27)	ND
Beta globulin (g/dL), m (SD)	0.34 (0.00)	0.81 (0.34)	ND
Gamma globulin (g/dL), m (SD)	0.75 (0.00)	1.35 (0.45)	ND
IgM (g/dL), m (SD)	180.00 (0.00)	105.33 (14.50)	ND
IgG (g/dL), m (SD)	1600 (0.00)	2366.66 (721.48)	ND
IgA (g/dL), m (SD)	358.00 (0.00)	331.00 (28.05)	ND

262 In the sub-group of women the one-way ANOVA test could not be performed
 263 because there was 1 patient with intestinal type gastric cancer. Abbreviations:
 264 TNM, tumor node metastasis; m, median; SD, standard deviation; IgM,
 265 immunoglobulin M; IgG, immunoglobulin G; IgA, immunoglobulin A; ND, not
 266 determined.

267 ^aOne-way ANOVA.

268

269 **Table 6. Levels of proteins, albumin, globulins and immunoglobulins**

270 **between patients with gastric cancer TNM stage IV from the different types.**

	Intestinal Gastric Cancer Patients	Diffuse Gastric Cancer Patients	p value
Total	(n=21)	(n=50)	
Proteins (g/dL), m (SD)	5.97 (1.39)	6.90 (2.13)	>0.05 ^a
Albumin (g/dL), m (SD)	3.36 (1.03)	3.77 (1.37)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.22 (0.20)	0.15 (0.12)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.44 (0.11)	0.54 (0.25)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.47 (0.21)	0.55 (0.25)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.47 (0.84)	1.82 (0.95)	>0.05 ^a
IgM (g/dL), m (SD)	105.28 (30.63)	127.48 (49.34)	>0.05 ^a
IgG (g/dL), m (SD)	2147.61 (536.77)	2095.00 (511.44)	>0.05 ^a
IgA (g/dL), m (SD)	351.23 (32.59)	359.74 (26.69)	>0.05 ^a
Men	(n=11)	(n=27)	
Proteins (g/dL), m (SD)	6.10 (1.59)	7.29 (2.44)	>0.05 ^a
Albumin (g/dL), m (SD)	3.35 (1.08)	4.01 (1.58)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.22 (0.12)	0.16 (0.14)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.46 (0.11)	0.57 (0.29)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.45 (0.25)	0.57 (0.28)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.58 (1.04)	1.93 (1.06)	>0.05 ^a
IgM (g/dL), m (SD)	112.90 (26.27)	118.51 (50.44)	>0.05 ^a
IgG (g/dL), m (SD)	2068.18 (363.53)	2011.48 (601.04)	>0.05 ^a

IgA (g/dL), m (SD)	361.36 (29.21)	361.22 (29.92)	>0.05 ^a
Women	(n=10)	(n=23)	
Proteins (g/dL), m (SD)	5.83 (1.19)	6.43 (1.63)	>0.05 ^a
Albumin (g/dL), m (SD)	3.36 (1.02)	3.50 (1.02)	>0.05 ^a
Alpha-1 globulin (g/dL), m (SD)	0.22 (0.27)	0.15 (0.08)	>0.05 ^a
Alpha-2 globulin (g/dL), m (SD)	0.43 (0.12)	0.49 (0.19)	>0.05 ^a
Beta globulin (g/dL), m (SD)	0.50 (0.17)	0.52 (0.21)	>0.05 ^a
Gamma globulin (g/dL), m (SD)	1.34 (0.57)	1.71 (0.83)	>0.05 ^a
IgM (g/dL), m (SD)	96.90 (34.19)	138.00 (46.92)	>0.05 ^a
IgG (g/dL), m (SD)	2235.00 (690.82)	2193.04 (370.20)	>0.05 ^a
IgA (g/dL), m (SD)	340.10 (33.91)	358.00 (22.87)	>0.05 ^a

271 Abbreviations: TNM, tumor node metastasis; m, median; SD, standard deviation;

272 IgM, immunoglobulin M; IgG, immunoglobulin G; IgA, immunoglobulin A.

273 ^aOne-way ANOVA.

274

275 **The albumin/globulin ratio in the intestinal and diffuse** 276 **types of gastric cancer, stratified by TNM stage**

277 Finally, the proportion of albumin/globulin was evaluated among patients with
 278 advanced gastric cancer, stratified by the intestinal and diffuse types, and by the
 279 TNM stage. In this evaluation, patients with diffuse gastric cancer of TNM stage
 280 IV presented more frequently values ≤ 1.2 than patients with intestinal gastric

281 cancer of TNM stage IV, which presented more frequently values ≥ 1.4 , $p \leq 0.5$
 282 (Dunn's Multiple Comparisons Test). The analysis is shown in Table 7.

283

284 **Table 7. The albumin/globulin ratio of patients with gastric cancer TNM**
 285 **stages III and IV, from the different types.**

Cancer type and TNM stage	Diffuse gastric cancer TNM stage III		Diffuse gastric cancer TNM stage IV		Intestinal gastric cancer TNM stage III		Intestinal gastric cancer TNM stage IV	
	<1.27	>1.27	<1.32	>1.32	<1.31	>1.31	<1.4	>1.4
A/G ratio	<1.27	>1.27	<1.32	>1.32	<1.31	>1.31	<1.4	>1.4
Men, n (%)	1 (25)	3 (75)	18 (66.6)	9 (33.3)	2 (100)	0 (0)	5 (45.4)	6 (54.5)
Women, n (%)	3 (100)	0 (0)	12 (52.1)	11 (47.9)	0 (0)	1 (100)	5 (50)	5 (50)

286 Abbreviations: TNM, tumor node metastasis; A/G, albumin/globulin; n, number;
 287 %, percentage; TNM, tumor node metastasis.

288

289 Discussion

290 In the demographic analysis, no relevant differences were observed
 291 between the groups of patients with intestinal and diffuse types of gastric cancer.
 292 The majority of patients with advanced gastric cancer were of the diffuse
 293 histological type (71%), which was expected as it is well described that gastric
 294 cancer of diffuse type has a more aggressive biological behavior, although lately,
 295 this aggressiveness has been attributed to a subgroup of diffuse gastric cancer

296 that presents with “linitis plastica”, a particularly aggressive infiltrative pattern
297 [18].

298 After comparing the concentrations of proteins and immunoglobulins
299 between the groups of patients with advanced gastric cancer from different TNM
300 stages (TNM stages III and IV), no differences were observed, and therefore,
301 according to the concentration of serum proteins and immunoglobulins, both
302 stages could be grouped into a single group of “advanced gastric cancer”.

303 One of the most interesting findings from this study was the difference observed
304 in IgG concentrations between healthy subjects and patients with advanced
305 gastric cancer of certain subgroups. Compared with the control group, the
306 subgroup of women with advanced gastric cancer (TNM stages III and IV) of any
307 type (intestinal and diffuse), and the subgroup of men with advanced gastric
308 cancer (TNM stage III) of the intestinal type, presented higher concentrations of
309 serum IgG. These results suggest that in certain subgroups of patients with
310 advanced gastric cancer there is an increase in the humoral immune response
311 related to IgG. When comparing these results with previous studies that have
312 evaluated other aspects of the humoral immune response in patients with gastric
313 cancer, there are concordances and contradictions. On the one hand, in one
314 study that evaluated the local humoral immune response, it was observed that in
315 patients with advanced gastric cancer there was an increase in IgG and a
316 depletion of IgM and IgA [10]. On the other hand, our results contradict the
317 previously reported one in which it was observed that patients with gastric cancer
318 had lower serum IgG levels than the control patients, however, this study

319 included patients with gastric cancer of all stages, and in our study, we included
320 Mexican patients with advanced gastric cancer (TNM stages III and IV), which
321 may explain the difference, since in advanced gastric cancer there is a greater
322 tumor burden and inflammation, which may explain an increased immunological
323 response to antigens from the tumor cells or as consequence of the increased
324 inflammatory response produced by the tumor, finally resulting in higher IgG
325 serum levels in the patients with advanced gastric cancer [12]. Kurtenkov, et. al.
326 have found elevated IgG anti-MUC1 autoantibodies in patients with gastric
327 cancer and also found that these autoantibodies were associated with cancer
328 progression [14]. We determined total IgG, which includes IgG antibodies and
329 normal IgG, and found high values in patients with advanced gastric cancer,
330 which could correlate with cancer progression too. This greater concentration of
331 serum IgG, could also be an antibody against an antigen associated with the
332 tumor that may favor the spread and metastasis, or may be an antibody
333 produced by the tumor cells to promote its development.

334 Another interesting finding of this study was that when we compared the
335 profile of serum proteins between patients with gastric cancer of different
336 histologic types, an increase in the concentration of the alpha-1 globulin fraction
337 was observed in the serum of patients with gastric cancer of the intestinal type.
338 Therefore, further studies are required to evaluate the profile of the alpha-1
339 fraction of serum proteins in patients with gastric cancer of the intestinal type,
340 with techniques that allow separation of all the fractions of proteins contained in
341 the alpha-1 fraction such as polyacrylamide gel electrophoresis, and then,

342 determine if these are already known proteins that are elevated as acute phase
343 reactants or if these are abnormal proteins secreted by the tumor cells. However,
344 we found in 36.7% of women with diffuse gastric cancer stage IV and in 5.9% of
345 women with diffuse gastric cancer stage III, low concentrations of alpha 1
346 globulin (α 1 anti-trypsin), which may be due to a hereditary genetic predisposition
347 in this type of cancer, and perhaps, because of the high percentage of patients in
348 which alpha 1 globulin is found, diminished or absent, the Mexican population
349 could carry a haplotype that makes them susceptible to this malignant disease. In
350 breast cancer, α 1 anti-trypsin, is a biomarker for early stages [19], in our patients
351 it is decreased in advanced stages, so we could consider it as a biomarker of
352 malignancy.

353 Further, we calculated the albumin/globulin ratio, this relationship is not
354 only related to the nutritional status but to the inflammatory response [20]. The
355 serum albumin is very important for the stabilization of DNA and inhibition of
356 carcinogenesis. It is well established that elevated albumin levels are associated
357 with a favorable prognosis of survival in several types of cancer [21]. Xue et al,
358 related the pre-surgery values of the albumin/globulin ratio to the prognosis of
359 gastric cancer, they found that a value <1.36 was associated with poor prognosis
360 [22]. These values have further been related to sex, age and size of the tumor
361 [23]. In our study, patients with diffuse gastric cancer stage IV predominated
362 (74%), and in this patients we found that 66% had an albumin/globulin ratio of
363 <1.2 , hence, this relationship could be considered as a prognostic indicator of
364 poor outcome from malignancy in Mexican population too.

365 Finally, in diffuse gastric cancer, the mutation of the gene of e-cadherin
366 CH1, is considered and hereditary risk factor, and in our study population, we
367 found a high prevalence of patients with diffuse gastric cancer in TNM stage IV,
368 with low values of alpha 1 globulin (alpha-1 antitrypsin) and low albumin/globulin
369 ratio, witch may be also related with a genetic predisposition. In some of these
370 patients, we have made the determination of E-cadherin, and we have found it
371 absent. For this reason, it's possible that the Mexican population may have an
372 allele, which makes them susceptible to diffuse gastric cancer type and an
373 aggressive course of this disease, witch may be in relation to a polymorphism of
374 the CDH1 gene specific to the Mexican population, as a genetic risk factor for
375 diffuse gastric cancer type [24].

376

377 **Conclusion**

378 In certain subgroups of patients with advanced gastric cancer there are
379 higher serum concentrations of serum IgG, the concentration of serum alpha-1
380 globulins is different between the intestinal and diffuse types of gastric cancer
381 and the albumin/globulin ratio is lower in the diffuse type of gastric caner. Further
382 studies are needed to determine the meaning of these differences.

383

384 Acknowledgments

385 This study was supported by the vice-rectory of research and
386 postgraduate studies from the Meritorious Autonomous University of Puebla,
387 Puebla, México. We thank all participating subjects for their cooperation in this
388 study, and all the doctors who helped to recruit the subjects in our study.

389

390 References

- 391 1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric
392 cancer. *Lancet*. 2016;388(10060):2654-2664. doi: 10.1016/S0140-
393 6736(16)30354-3.
- 394 2. Yamashita K, Sakuramoto S, Katada N, Futawatari N, Moriya H, Hirai K,
395 et al. Diffuse type advanced gastric cancer showing dismal prognosis is
396 characterized by deeper invasion and emerging peritoneal cancer cell:
397 The latest comparative study to intestinal advanced gastric cancer.
398 *Hepatogastroenterology*. 2009;56:276–281. doi: not available.
- 399 3. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, et al.
400 Pathobiological characteristics of intestinal and diffuse-type gastric
401 carcinoma in Japan: An immunostaining study on the tissue microarray. *J*
402 *Clin Pathol*. 2007;60:273–277. doi: 10.1136/jcp.2006.038778.
- 403 4. Chen YC, Fang WL, Wang RF, Liu CA, Yang MH, Lo SS, et al.
404 Clinicopathological variation of lauren classification in gastric cancer.
405 *Pathol Oncol Res*. 2016;22:197–202. doi: 10.1007/s12253-015-9996-6.

- 406 5. Wang H, Xing XM, Ma LN, Liu L, Hao J, Feng LX, et al. Metastatic lymph
407 node ratio and Lauren classification are independent prognostic markers
408 for survival rates of patients with gastric cancer. *Oncol Lett*.
409 2018;15(6):8853-8862. doi: 10.3892/ol.2018.8497.
- 410 6. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al.
411 Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in
412 Oncology. *J Natl Compr Canc Netw*. 2016;14(10):1286-1312. doi: not
413 available.
- 414 7. Yuan DD, Zhu ZX, Zhang X, Liu J. Targeted therapy for gastric cancer:
415 Current status and future directions (Review). *Oncol Rep*.
416 2016;35(3):1245-1254. doi: 10.3892/or.2015.4528.
- 417 8. Matsueda S, Graham DY. Immunotherapy in gastric cancer. *World J*
418 *Gastroenterol*. 2014;20(7):1657-1666. doi: 10.3748/wjg.v20.i7.1657.
- 419 9. Li K, Dan Z, Nie YQ. Gastric cancer stem cells in gastric carcinogenesis,
420 progression, prevention and treatment. *World J Gastroenterol*.
421 2014;20(18):5420-5426. doi: 10.3748/wjg.v20.i18.5420.
- 422 10. Takemura K, Hirokawa K, Esaki Y, Mishima Y. Distribution of
423 immunoglobulins and secretory component in gastric cancer of the aged.
424 *Cancer*. 1990;66(10):2168-2173. doi: 10.1002/1097-
425 0142(19901115)66:10<2168::aid-cnrcr2820661021>3.0.co;2-2.
- 426 11. Yolanda LV, Sergio PD, Hugo ES, Isabel AF, Rafael BZ, Aldo TD, et al.
427 Gastric cancer progression associated with local humoral immune
428 responses. *BMC Cancer*. 2015;15:924. doi: 10.1186/s12885-015-1858-9.

- 429 12. Wu CW, Lui WY, P'eng FK, Wang SR. Alterations of humoral immunity in
430 patients with gastric cancer. *Asian Pac J Allergy Immunol.* 1988;6(1):7-10.
431 doi: not available.
- 432 13. Pandey JP, Nietert PJ, von Mensdorff-Pouilly S, Klaamas K, Kurtenkov O.
433 Immunoglobulin allotypes influence antibody responses to mucin 1 in
434 patients with gastric cancer. *Cancer Res.* 2008;68(11):4442-4446. doi:
435 10.1158/0008-5472.CAN-07-5607.
- 436 14. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova
437 L, Chuzmarov V. Humoral immune response to MUC1 and to the
438 Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer:
439 relation to survival. *Acta Oncol.* 2007;46(3):316-323. doi:
440 10.1080/02841860601055441.
- 441 15. Krueziger Keppy N, Allen M. The Biuret Method for the Determination of
442 Total Protein Using an Evolution Array 8-Position Cell Changer. Thermo
443 Fisher Scientific Inc. 2009, Application Note: 51859. doi: not available.
- 444 16. Lubran MM. The Measurement of Total Serum Proteins by the Biuret
445 Method. *Annals of clinical and laboratory science.* 1979;8(2);106-110. doi:
446 not available.
- 447 17. Suga S, Tamura Z. Analysis of Serum Protein Changes in Patients with
448 Advanced Gastric Cancer with Special Reference to a-Globulin Fractions.
449 *Cancer Research.* 1972;32,426-429. doi: not available.

- 450 18. Luu C, Thapa R, Woo K, Coppola D, Almhanna K, Pimiento JM, et al.
451 Does histology really influence gastric cancer prognosis? *J Gastrointest*
452 *Oncol.* 2017;8(6):1026-1036. doi: 10.21037/jgo.2017.09.08.
- 453 19. López-Árias E, Aguilar-Lemarroy A, Felipe Jave-Suárez L, Morgan-Villela
454 G, Mariscal-Ramírez I, Martínez-Velázquez M, et al. Alpha 1-antitrypsin: A
455 novel tumor-associated antigen identified in patients with early-stage
456 breast cancer. *Electrophoresis.* 2012;33:2130–2137. doi:
457 10.1002/elps.201100491.
- 458 20. Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B.
459 Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or
460 inflammatory surrogate? *World J Gastrointest Surg.* 2015;7(12):370-377.
461 doi: 10.4240/wjgs.v7.i12.370.
- 462 21. Chen J, Zhou Y, Xu Y, Zhu HY, Shi YQ. Low pretreatment serum globulin
463 may predict favorable prognosis for gastric cancer patients. *Tumor Biol.*
464 2016;37(3):3905–3911. doi: 10.1007/s13277-015-3778-3.
- 465 22. Xue F, Lin F, Yin M, Feng N, Zhang X, Cui YG, et al. Preoperative
466 albumin/globulin ratio is a potential prognosis predicting biomarker in
467 patients with resectable gastric cancer. *Turk J Gastroenterol.*
468 2017;28(6):439-445. doi: 10.5152/tjg.2017.17167.
- 469 23. Toiyama Y, Yasuda H, Ohi M, Yoshiyama S, Araki T, Tanaka K, et al.
470 Clinical impact of preoperative albumin to globulin ratio in gastric cancer
471 patients with curative intent. *Am J Surg.* 2017;213(1):120-126. doi:
472 10.1016/j.amjsurg.2016.05.012.

473 24. Oliveira C, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC,
474 et al. Screening E-cadherin in gastric cancer families reveals germline
475 mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat.
476 2002;19(5):510-517. doi: 10.1002/humu.10068.